Alpha-Synuclein and the Endolysosomal System in Parkinson's Disease: Guilty by Association

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Sep 28

PMID 34572546

Citations 24

Authors

Maxime Teixeira

Razan Sheta

Walid Idi

Abid Oueslati

Affiliations

Soon will be listed here.

Abstract

Abnormal accumulation of the protein α- synuclein (α-syn) into proteinaceous inclusions called Lewy bodies (LB) is the neuropathological hallmark of Parkinson's disease (PD) and related disorders. Interestingly, a growing body of evidence suggests that LB are also composed of other cellular components such as cellular membrane fragments and vesicular structures, suggesting that dysfunction of the endolysosomal system might also play a role in LB formation and neuronal degeneration. Yet the link between α-syn aggregation and the endolysosomal system disruption is not fully elucidated. In this review, we discuss the potential interaction between α-syn and the endolysosomal system and its impact on PD pathogenesis. We propose that the accumulation of monomeric and aggregated α-syn disrupt vesicles trafficking, docking, and recycling, leading to the impairment of the endolysosomal system, notably the autophagy-lysosomal degradation pathway. Reciprocally, PD-linked mutations in key endosomal/lysosomal machinery genes (LRRK2, GBA, ATP13A2) also contribute to increasing α-syn aggregation and LB formation. Altogether, these observations suggest a potential synergistic role of α-syn and the endolysosomal system in PD pathogenesis and represent a viable target for the development of disease-modifying treatment for PD and related disorders.

Citing Articles

Synaptic sabotage: How Tau and α-Synuclein undermine synaptic health.

Uytterhoeven V, Verstreken P, Nachman E J Cell Biol. 2024; 224(2).

PMID: 39718548 PMC: 11668179. DOI: 10.1083/jcb.202409104.

Lipids and α-Synuclein: adding further variables to the equation.

Schepers J, Loser T, Behl C Front Mol Biosci. 2024; 11:1455817.

PMID: 39188788 PMC: 11345258. DOI: 10.3389/fmolb.2024.1455817.

CNS cell-derived exosome signatures as blood-based biomarkers of neurodegenerative diseases.

Park C, Weerakkody J, Schneider R, Miao S, Pitt D Front Neurosci. 2024; 18:1426700.

PMID: 38966760 PMC: 11222337. DOI: 10.3389/fnins.2024.1426700.

In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro.

Lenzi P, Lazzeri G, Ferrucci M, Busceti C, Puglisi-Allegra S, Fornai F J Neural Transm (Vienna). 2024; 131(12):1397-1414.

PMID: 38890195 PMC: 11608283. DOI: 10.1007/s00702-024-02795-x.

Distinct ultrastructural phenotypes of glial and neuronal alpha-synuclein inclusions in multiple system atrophy.

Boing C, Di Fabrizio M, Burger D, Bol J, Huisman E, Rozemuller A Brain. 2024; 147(11):3727-3741.

PMID: 38696728 PMC: 11531854. DOI: 10.1093/brain/awae137.

References

Abeliovich A, Gitler A . Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature. 2016; 539(7628):207-216. DOI: 10.1038/nature20414. View

Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton M, Sudhof T . Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010; 329(5999):1663-7. PMC: 3235365. DOI: 10.1126/science.1195227. View

Hoffmann A, Minakaki G, Menges S, Salvi R, Savitskiy S, Kazman A . Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. Sci Rep. 2019; 9(1):544. PMC: 6345801. DOI: 10.1038/s41598-018-35811-8. View

Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

Lashuel H, Overk C, Oueslati A, Masliah E . The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012; 14(1):38-48. PMC: 4295774. DOI: 10.1038/nrn3406. View

Alcalay R, Levy O, Waters C, Fahn S, Ford B, Kuo S . Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015; 138(Pt 9):2648-58. PMC: 4564023. DOI: 10.1093/brain/awv179. View

Klucken J, Poehler A, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E . Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy. 2012; 8(5):754-66. PMC: 3378419. DOI: 10.4161/auto.19371. View

Mahul-Mellier A, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F . The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020; 117(9):4971-4982. PMC: 7060668. DOI: 10.1073/pnas.1913904117. View

Winner B, Jappelli R, Maji S, Desplats P, Boyer L, Aigner S . In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011; 108(10):4194-9. PMC: 3053976. DOI: 10.1073/pnas.1100976108. View

10.

Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S . Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 2006; 52(2):293-305. DOI: 10.1016/j.neuron.2006.08.018. View

11.

Zunke F, Moise A, Belur N, Gelyana E, Stojkovska I, Dzaferbegovic H . Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron. 2018; 97(1):92-107.e10. PMC: 6013314. DOI: 10.1016/j.neuron.2017.12.012. View

12.

Shi M, Shi C, Xu Y . Rab GTPases: The Key Players in the Molecular Pathway of Parkinson's Disease. Front Cell Neurosci. 2017; 11:81. PMC: 5369176. DOI: 10.3389/fncel.2017.00081. View

13.

Liu J, Zhang J, Shi M, Quinn T, Bradner J, Beyer R . Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci. 2009; 29(5):1480-5. PMC: 3241981. DOI: 10.1523/JNEUROSCI.6202-08.2009. View

14.

Dalfo E, Barrachina M, Rosa J, Ambrosio S, Ferrer I . Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiol Dis. 2004; 16(1):92-7. DOI: 10.1016/j.nbd.2004.01.001. View

15.

Olgiati S, Quadri M, Fang M, Rood J, Saute J, Chien H . DNAJC6 Mutations Associated With Early-Onset Parkinson's Disease. Ann Neurol. 2015; 79(2):244-56. DOI: 10.1002/ana.24553. View

16.

Williams E, Chen X, Moore D . VPS35, the Retromer Complex and Parkinson's Disease. J Parkinsons Dis. 2017; 7(2):219-233. PMC: 5438477. DOI: 10.3233/JPD-161020. View

17.

Chandra S, Gallardo G, Fernandez-Chacon R, Schluter O, Sudhof T . Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005; 123(3):383-96. DOI: 10.1016/j.cell.2005.09.028. View

18.

Desplats P, Lee H, Bae E, Patrick C, Rockenstein E, Crews L . Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106(31):13010-5. PMC: 2722313. DOI: 10.1073/pnas.0903691106. View

19.

Sacino A, Brooks M, Chakrabarty P, Saha K, Khoshbouei H, Golde T . Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. J Neurochem. 2016; 140(4):662-678. PMC: 5452425. DOI: 10.1111/jnc.13743. View

20.

Yu W, Dorado B, Figueroa H, Wang L, Planel E, Cookson M . Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol. 2009; 175(2):736-47. PMC: 2716969. DOI: 10.2353/ajpath.2009.080928. View